Id |
Subject |
Object |
Predicate |
Lexical cue |
T123 |
0-23 |
Sentence |
denotes |
4.2 Anti-S2 antibodies |
T124 |
24-202 |
Sentence |
denotes |
In contrast to RBD, the fusion domains are more difficult to access due to the tight folding of viral glycoproteins or the excessively transient exposure during the fusion stage. |
T125 |
203-263 |
Sentence |
denotes |
This is why few epitopes are described in these regions [6]. |
T126 |
264-432 |
Sentence |
denotes |
Interestingly, the S2 specific mAbs can neutralize pseudotyped viruses which expressing different S proteins containing RBD sequences of various clinical isolates [47]. |
T127 |
433-468 |
Sentence |
denotes |
The S2 protein is highly conserved. |
T128 |
469-596 |
Sentence |
denotes |
No mutation in HR1 was reported in an analysis of the amino acid sequences of the S protein from 94 SARS-CoV clinical isolates. |
T129 |
597-700 |
Sentence |
denotes |
Only few mutations in HR2, at amino acids K1163 or Q1183 for example, were observed in this study [47]. |
T130 |
701-746 |
Sentence |
denotes |
Some S2 epitopes inducing nAbs were reported. |
T131 |
747-819 |
Sentence |
denotes |
A peptide containing aa 1055–1192 can elicit neutralizing activity [48]. |
T132 |
820-1041 |
Sentence |
denotes |
Two other proteins Trx-F3 and Trx-F9 containing linear antigenic determinants (Leu 803 to Ala 828 and Pro 1061 to Ser 1093, respectively) on the S2 domain were identified by using sera from convalescent SARS-CoV patients. |
T133 |
1042-1099 |
Sentence |
denotes |
Trx-F3 was capable of inducing nAbs in some animals [49]. |
T134 |
1100-1272 |
Sentence |
denotes |
Some human mAbs anti-HR1 (1F8, 1D12, 2A12, 2B12, 4A4, 4F9, 5C3, 6C9, 6H2) and anti-HR2 (1E10, 2D2, 2D6, 3A11, 3E10, 3H11, 5B9, 5B10, 5D7, 5E9, 5G8, 5G9, 6H1) were reported. |
T135 |
1273-1462 |
Sentence |
denotes |
With these Abs, the authors showed that the combination of HmAbs targeting different regions of the S protein would likely increase the broad neutralization against different isolates [47]. |
T136 |
1463-1562 |
Sentence |
denotes |
A human scFv antibody, named B1, showed a high affinity to an epitope (aa 1023–1189) on S2 protein. |
T137 |
1563-1651 |
Sentence |
denotes |
This antibody also showed potent neutralizing activities against SARS-CoV in vitro [50]. |
T138 |
1652-1754 |
Sentence |
denotes |
B1, 1F8 and 5E9 nAbs against epitopes on SARS-CoV S2 also showed effectiveness in neutralization [51]. |
T139 |
1755-1849 |
Sentence |
denotes |
The protective immunity by the time in patients after SARS-CoV natural infection was observed. |
T140 |
1850-1965 |
Sentence |
denotes |
After 6 years, the humoral immunity continuously decreased and eventually disappeared in most infected individuals. |
T141 |
1966-2070 |
Sentence |
denotes |
The IgG Ab could be an indicator of neutralizing Ab for the humoral response to SARS-CoV infection [52]. |